Literature DB >> 32372243

Using Supervised Learning Methods to Develop a List of Prescription Medications of Greatest Concern during Pregnancy.

Elizabeth C Ailes1, John Zimmerman2, Jennifer N Lind3, Fanghui Fan2, Kun Shi2, Jennita Reefhuis3, Cheryl S Broussard3, Meghan T Frey3, Janet D Cragan3, Emily E Petersen4, Kara D Polen3, Margaret A Honein3, Suzanne M Gilboa3.   

Abstract

INTRODUCTION: Women and healthcare providers lack adequate information on medication safety during pregnancy. While resources describing fetal risk are available, information is provided in multiple locations, often with subjective assessments of available data. We developed a list of medications of greatest concern during pregnancy to help healthcare providers counsel reproductive-aged and pregnant women.
METHODS: Prescription drug labels submitted to the U.S. Food and Drug Administration with information in the Teratogen Information System (TERIS) and/or Drugs in Pregnancy and Lactation by Briggs & Freeman were included (N = 1,186 medications; 766 from three data sources, 420 from two). We used two supervised learning methods ('support vector machine' and 'sentiment analysis') to create prediction models based on narrative descriptions of fetal risk. Two models were created per data source. Our final list included medications categorized as 'high' risk in at least four of six models (if three data sources) or three of four models (if two data sources).
RESULTS: We classified 80 prescription medications as being of greatest concern during pregnancy; over half were antineoplastic agents (n = 24), angiotensin converting enzyme inhibitors (n = 10), angiotensin II receptor antagonists (n = 8), and anticonvulsants (n = 7). DISCUSSION: This evidence-based list could be a useful tool for healthcare providers counseling reproductive-aged and pregnant women about medication use during pregnancy. However, providers and patients may find it helpful to weigh the risks and benefits of any pharmacologic treatment for both pregnant women and the fetus when managing medical conditions before and during pregnancy.

Entities:  

Keywords:  Birth defects; Congenital malformations; Medication; Pregnancy; Teratogen; Teratology

Mesh:

Substances:

Year:  2020        PMID: 32372243      PMCID: PMC7482428          DOI: 10.1007/s10995-020-02942-2

Source DB:  PubMed          Journal:  Matern Child Health J        ISSN: 1092-7875


  29 in total

1.  Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.

Authors:  Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz
Journal:  Am J Obstet Gynecol       Date:  2011-04-22       Impact factor: 8.661

2.  Maternal progestin intake and risk of hypospadias.

Authors:  Suzan L Carmichael; Gary M Shaw; Cecile Laurent; Mary S Croughan; Richard S Olney; Edward J Lammer
Journal:  Arch Pediatr Adolesc Med       Date:  2005-10

Review 3.  Evolving knowledge of the teratogenicity of medications in human pregnancy.

Authors:  Margaret P Adam; Janine E Polifka; J M Friedman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-07-15       Impact factor: 3.908

4.  Discrepancies in the Evidence and Recommendation Levels of Pregnancy Information in Prescription Drug Labeling in the United States, United Kingdom, Japan, and Korea.

Authors:  Yunha Noh; Dongwon Yoon; Inmyung Song; Han Eol Jeong; Ji Hwan Bae; Ju-Young Shin
Journal:  J Womens Health (Larchmt)       Date:  2018-06-07       Impact factor: 2.681

5.  2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.

Authors:  Erik K Alexander; Elizabeth N Pearce; Gregory A Brent; Rosalind S Brown; Herbert Chen; Chrysoula Dosiou; William A Grobman; Peter Laurberg; John H Lazarus; Susan J Mandel; Robin P Peeters; Scott Sullivan
Journal:  Thyroid       Date:  2017-03       Impact factor: 6.568

Review 6.  Prescription drugs and pregnancy.

Authors:  William S Webster; Jane A D Freeman
Journal:  Expert Opin Pharmacother       Date:  2003-06       Impact factor: 3.889

Review 7.  Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline.

Authors:  Leslie De Groot; Marcos Abalovich; Erik K Alexander; Nobuyuki Amino; Linda Barbour; Rhoda H Cobin; Creswell J Eastman; John H Lazarus; Dominique Luton; Susan J Mandel; Jorge Mestman; Joanne Rovet; Scott Sullivan
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

8.  The Most Commonly Dispensed Prescription Medications Among Pregnant Women Enrolled in the U.S. Medicaid Program.

Authors:  Kristin Palmsten; Sonia Hernández-Díaz; Christina D Chambers; Helen Mogun; Sophia Lai; Todd P Gilmer; Krista F Huybrechts
Journal:  Obstet Gynecol       Date:  2015-09       Impact factor: 7.661

9.  Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists.

Authors:  Molly M Lynch; Jacqueline B Amoozegar; Emily M McClure; Linda B Squiers; Cheryl S Broussard; Jennifer N Lind; Kara N Polen; Meghan T Frey; Suzanne M Gilboa; Janis Biermann
Journal:  Qual Health Res       Date:  2017-10-03

10.  Multiple information sources and consequences of conflicting information about medicine use during pregnancy: a multinational Internet-based survey.

Authors:  Katri Hämeen-Anttila; Hedvig Nordeng; Esa Kokki; Johanna Jyrkkä; Angela Lupattelli; Kirsti Vainio; Hannes Enlund
Journal:  J Med Internet Res       Date:  2014-02-20       Impact factor: 5.428

View more
  1 in total

Review 1.  Advances of Sentiment Analysis Applications in Obstetrics/Gynecology and Midwifery.

Authors:  Stavroula G Barbounaki; Kleanthi Gourounti; Antigoni Sarantaki
Journal:  Mater Sociomed       Date:  2021-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.